Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab + FOLFOX in Stage III dMMR Colon Cancer
NCT02912559Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Oct 2017
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 3, randomised, open-label trial of atezolizumab in colon cancer (2 arms), sponsored by National Cancer Institute. Primary endpoint: Disease Free Survival at 3 years. Started Oct 2017; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
colon cancer
Beyond the preview
Go deeper on NCT02912559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02912559.